Pu Yanchuan, Wang Jin, Wang Jianshu, Wang Shizhong
Department of Orthopedics, Wuwei City People's Hospital, Wuwei, China.
Department of Bone Oncology, Gansu Cancer Hospital, Lanzhou, China.
Front Oncol. 2022 Apr 8;12:699295. doi: 10.3389/fonc.2022.699295. eCollection 2022.
We aimed to evaluate the utility of preoperative D-dimer and plasma fibrinogen (PF) levels as useful markers for predicting the clinical value of patients with osteosarcoma.
145 enrolled patients with osteosarcoma were studied retrospectively. We determined the critical values of D-dimer and PF by receiver operating characteristic curve analysis. Cox regression analysis was used to assess prognostic role of the D-dimer and PF levels among osteosarcoma patients.
The critical values of D-dimer and PF were calculated to be 0.46 µg/mL and 3.34 mg/mL, respectively. Upregulation of D-dimer and PF showed positive correlations with a higher clinical stage, tumour metastasis and recurrence. Survival curve results confirmed that osteosarcoma patients with higher levels of D-dimer and PF predicted worse overall survival (OS) and progression-free survival (PFS). Moreover, only a high D-dimer level was associated with a shorter OS (P = 0.013) and PFS (P = 0.042) in both the univariate and multivariate analysis.
Elevated preoperative D-dimer levels are correlated with aggressive clinicopathological features and poor survival outcomes, which indicates that assessment of the D-dimer could be a useful prognostic marker in osteosarcoma.
我们旨在评估术前D-二聚体和血浆纤维蛋白原（PF）水平作为预测骨肉瘤患者临床价值的有用标志物的效用。
对145例纳入研究的骨肉瘤患者进行回顾性研究。我们通过受试者工作特征曲线分析确定D-二聚体和PF的临界值。采用Cox回归分析评估D-二聚体和PF水平在骨肉瘤患者中的预后作用。
D-二聚体和PF的临界值分别计算为0.46μg/mL和3.34mg/mL。D-二聚体和PF的上调与更高的临床分期、肿瘤转移和复发呈正相关。生存曲线结果证实，D-二聚体和PF水平较高的骨肉瘤患者的总生存期（OS）和无进展生存期（PFS）较差。此外，在单因素和多因素分析中，只有高D-二聚体水平与较短的OS（P = 0.013）和PFS（P = 0.042）相关。
术前D-二聚体水平升高与侵袭性临床病理特征和不良生存结果相关，这表明D-二聚体评估可能是骨肉瘤中一种有用的预后标志物。
